Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1996-02-29
1997-12-16
Lankford, Jr., Leon B.
Drug, bio-affecting and body treating compositions
Lymphokine
424 852, 424 854, 424 855, 435 704, 435 705, A61K 4505
Patent
active
056981945
ABSTRACT:
A method of producing a natural nonrecombinant cytokine mixture is disclosed including the steps of immobilizing at least one mitogen in a tissue culture vessel. An isolated population of lymphocytes free of neutrophils and erythrocytes, is suspended in a serum-free media and placed in the vessel. The lymphocytes are cultured, the media removed, and characterized for the yield of cytokines.
REFERENCES:
patent: 4390623 (1983-06-01), Fabricius et al.
patent: 4448879 (1984-05-01), Fabricius et al.
patent: 4464355 (1984-08-01), Fabricius et al.
Alvarez et al., "Human T cell growth factor" The Journal of Immunology, vol. 123, No. 3, pp. 977-984 (1979).
Lafferty et al., "Immunological induction of T lymphocytes: role of antigen and the lymphocyte costimualtor" Blood Cells, 4:395-404 (1978).
Talmage et al., "Activation of cytotoxic T cells by nonstimulating tumor cells and spleen cell factor(s)" Proc. Natl. Acad. Sci. USA, vol. 74, No. 10, pp. 4610-4614 (1977).
Vine et al. J. Immunology, 141(8). 1988, 2593-2600.
Mitchell et al, J. Immunology 142(5), 1989, 1548-1557.
Gollapudi et al. Antimicrob Agents Chemother. 29(2). 1986 pp. 337-338.
AIS Technical Bulletin No. 9003, "Covalent Immobilization of Antibodies to Protein-Reactive Polystyrene".
Belldegrun and Rosenberg, "Adoptive immunotherapy of urologic tumors" Cancer Treat. Res. 46:213-233, 1989.
Bender et al., "Absolute Peripheral Blood Lymphocyte Count and Subsequent Mortality of Elderly Men" JAGS 34:649-654, 1986.
BioWhittaker Brochure, "Adoptive Immunotherapy and Genetic Therapy".
Borden, "Interferons: Rationale for Clinical Trials in Neoplastic Disease", Ann, Int. Med. 91:492-499, 1979.
Chang and Rosenberg, "Overview of Interleukin-2 as Immunotherapeutic Agent" Semin. Surg. Oncol., 5(6):385-90, 1989.
Chilson and Kelly-Chilson, "Mitogenic Lectins Binds to the Antigen Receptor on Human Lymphocytes" Eur. J. Immunol., 19:389-396, 1989.
Chirigos and Talmadge, "Immunotherapeutic Agents Their Role in Cellular Immunity and Their Therapeutic Potential" Springer Seminars in Immunopathol., 8:327-336, 1985.
Cortesina et al., "Monoclonal Antibodies against Epithelial Antigens . . . " J. Laryngol Otol. 102(8):709-12, 1988.
Cortesina et al., "Temporary Regression of Recurrent Squamous Cell Carcinoma of the Head and Neck . . . " Br. J. Cancer, 69:572-576, 1994.
Deans et al., "CD45R as a Primary Signal Transducer Stimulating IL-2 and IL-2R mRNA Systhesis by CD3 4 8 Thymocytes" J. Immunol., 143:2425-2430, 1989.
DeSimone et al., "Report of the Symposium on the Use of Intravenous Gammaglobulin (IVIG) in Adults Infected with HIV" J. Clin. Lab. Anal. 4:313-317, 1990.
Devos, "Molecular cloning of human interleukin 2 cDNA and its expression in E. coli" Nucleic Acids Res., 11:4307-4323, 1983.
Forni et al., "Interleukin 2 Activated Tumor Inhibition in vivo depends on the systemic involvement of host immunoreactivity" J. Immunol. 138:4033-41, 1987.
Gillis et al., "T Cell Growth Factor: Parameters of Production and a Quantitive Microassay for Activity" J. Immunol., 120:2027-2032, 1978.
Goldstein and Laslo, "The Role of Interferon in Cancer Therapy: A Current Perspective" Ca-A Cancer Journal For Clinicians, 38:258-290, 1988.
Hadden, "Immunotherapy of Human Immunodeficiency Virus (HIV)" TIPS, 12:107-111, 1991.
Hadden, "Thymic Endocrinology" Int. J. Immunopharmacol., 14:345-352, 1991.
Hadden, "Immunostimulants" Immunology Today 276, vol. 14, No.6, 1993.
Hadden, "T-Cell Adjuvants", Int. J. Immunopharmacol., vol. 16, No. 9, pp. 703-710, 1994.
Hadden and Smith, "Immunopharmacology" JAMA, 268:2964-2969, 1992.
Hadden et al., "Lymphocyte Blast Transformation I. Demonstration of Adrenergic Receptors in Human Peripheral Lymphocytes" J. Cell. Immununol. 1:583-595, 1970.
Hadden et al., "Strategies of Immune Reconstitution: Effects of of Lymphokines . . . " Life Sci. 44:V-XII, 1989.
Hadden et al., "The Characterization of Immunotheraputic Agents" In Immunopharmology Reviews, Plenum Press, NY, pp.1-64, 1990.
Hadden et al., "Mixed Interleukins and Thymosin Fraction V Synergistically Induce T Lymphocyte Development in Hydrocortisone . . . " Cell. Immunol. 144:228-236, 1992.
Hadden et al., "Interleukins and Contrasuppression Induce Immune Regression of Head and Neck Cancer" Int. Arch. Otolaryngol., 120:395-403, 1994.
Hall, "Immunomodulation with Intravenous Immunoglobulin" Pharmacotherapy, 13(6):564-73, Nov.-Dec. 1993.
Hwu and Rosenberg, "The Use of Gene-Modified Tumor-Infiltrating Lymphocytes for Cancer Therapy" Ann. N.Y. Acad. Sci. 716:188-203, 1994a.
Hwu and Rosenberg, "The Genetic Modification of T Cells for Cancer Therapy: An Overview of Laboratory and Clinical Trials" Cancer Detect. Prev. 18(1):43-50 1994b.
IGIV News Update, "An Extra Measure of Viral Safety" vol. 1, No. 2, Dec., 1993.
June et al., "Evidence for the Involvement of Three Distinct Signals in the Induction of IL-2 . . . " J. Immunol., 143:153-161, 1989.
Kameda et al., "Mixed Lymphokines in Low Dose Prolong Life in Cyclophosphamide-Treated Melanoma-Bearing Mice" Int. J. Innunother. 8:1-5, 1992.
Lane and Fauci, "Therapeutic Approaches to the Underlying Immune Deficit in AIDS" Abstracts Int. Conf. on AIDS, Paris, 1986.
Mattijssen et al. "Clinicial and Immunopathological Results of a Phase II Study of Perilymphatically . . . " J. Immunother. 10:63-68, 1991.
Merigan, In: Combination Anti HIV Therapy in Combination Therapy 2 eds. Garaci and Goldstein, Plenum Press, pp.225-229, 1993.
Mishell and Shiigi, "Selected Methods in Cellular Immunology" Freeman, pp. 23-24, 1981.
Morgan et al., "Selective in vitro Growth of T Lymphocytes from Normal Human Bone Marrows" Science, 193:1007-8, 1976.
Mule and Rosenberg, "Mechanistic Aspects of Successful Immunotherapy." Prog. Clin. Biol., 244:79-91, 1987.
Mutch and Hutson, "Levamisole in the Adjuvant Treatment of Colon Cancer", Clin. Pharmacol. 10:95-109, 1991.
Paetkeau et al., J. Immunol., 117:1320-4, 1976.
Pulley et al., "Intravenous, Intralesional and Endolymphatic Administration of Lympokines in Human Cancer" Lymphokin Research, vol.5, Supplement 1, pp. S-157-S163, 1986.
Riesenbeck et al., "Superinduction of Cytokine Gene Transcription by Ciprofloxacin" J. Immunol., 153:343-352, 1994.
Rosenberg et al., "Observations on the systemic administration of autologous lymphokine-activated killer cells . . . " New Eng. J. Med. 313:1485-1492, 1985.
Rosenberg, "The development of new immunotherapies for treatment of of cancer using interleukin-2" Ann Surg. 208(2):121-135, Aug. 1988.
Rosenberg, in The Transformed Cell, p. 109, Putnam Sons, New York, 1992.
Rosenberg, J. Biol. Resp. Mod. 3:501-511, 1994.
Spreafico, "Use of levamisole in cancer patients" Drugs 19:105-116, 1980.
Symoens and Rosenthal, "Levamisole in the modulation of immune response: the current experimental and clinical state" J. Reticuloendothel. Soc. 21:175-219, 1977.
Talmadge et al., in Screening for Biological Response Modifiers: Methods and Rationale, Martinus Nijhoff, Boston, pp.121-129 and pp. 181-182, 1985.
Talmadge and Hadden, "An update on immunopharmacology of recombinant and synthetic . . . " in Immunoregulators in Therapy and Disease (Marcel Dekker, NY) 1993.
Taniguchi et al., "Structure and expression of a cloned cDNA for human interleukin-2" Nature, 302:305-310, 1983.
Thurman et al., J. Biol. Response Modif. 5:85-107, 1986.
Webb et al., "Mitogen-induced human lymphocyte activation in serum-free medium" Clinical Immunology and Immunopathology, 1:304-310, 1973.
Kovacs et al., "Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 . . . " New Eng. J. Med. 332:567-575, 1995.
Lankford , Jr. Leon B.
University of South Florida
LandOfFree
Method for making a medicament for treating secondary immunodefi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for making a medicament for treating secondary immunodefi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for making a medicament for treating secondary immunodefi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-202931